UNSPSC 51191546: Etacrynic acid or ethacrynic acid

This classification denotes a loop diuretic with the molecular formula C13H12Cl2O4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier M5DP350VZV, chemically known as 2,3-dichloro-4-(2-methylenebutyryl)phenoxy acetic acid but more generally known as etacrynic acid, which bears US NIH Compound Identifier 3278. European Medicines Agency schedules Etacrynic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07255MIG.

The term ETACRYNIC ACID is an International Non-Proprietary Name World Health Organization schedules etacrynic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Ethacrynic acid bears US NLM identifiers UMLS ID C0014963 and NCI Concept Code C485. SMILES: CLC1C(C(=O)C(=C)CC)CCC(OCC(=O)O)C1CL.

UNSPSC 51191546 Etacrynic acid or ethacrynic acid is a Commodity code that in recent state and local procurement activity covers generic pharmaceutical and chemical products supplied to public health and water treatment operations. The code shows minimal alignment with its nominal scope; recent solicitations tagged to this code actually buy sodium bisulfite for municipal water treatment and generic pharmaceuticals and over-the-counter products for state and local government health facilities through cooperative purchasing vehicles. Issuing bodies include city departments (municipal water authorities), state procurement offices administering multi-state cooperative purchasing alliances, and health-facility networks across multiple states. The work solicited spans chemical supply contracts with firm unit-price bidding and performance bonding, and pharmaceutical supply contracts with manufacturer-to-wholesaler distribution through cGMP-compliant supply chains and chargeback systems.

The City of Meriden, Connecticut issued IFB B02715 for sodium bisulfite chemical supply to its Water Pollution Control Facility with a due date of July 29, 2026, requiring $1,000,000 to $2,000,000 General Liability coverage and performance bonding. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 with a March 26, 2026 response deadline to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota, Oregon, and other member jurisdictions, with products distributed through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and awards effective July 1, 2026. The pharmaceutical RFP weights price competitiveness at 75 percent and requires vendors to maintain $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability coverage. Connecticut and Minnesota show the most recent identifiable activity under the code, though the mismatch between the code's pharmaceutical name and the actual commodities being procured (water-treatment chemicals and multi-source generic drugs) signals that this code may carry inconsistent tagging in state and local systems.